Omalizumab for the treatment of solar urticaria: case series and systematic review of the literature

Conclusion Omalizumab provided clinical benefits in approximately 80% of SU patients. Patients failing to improve on standard omalizumab doses may benefit from higher monthly dosages.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research